Please check your internet connection and try again.
# Methylcobalamin
## Overview
Methylcobalamin is a biologically active form of Vitamin B12 (cobalamin). Unlike cyanocobalamin, it does not require conversion by the liver and acts as a cofactor for methionine synthase, essential for DNA and protein synthesis, and myelin sheath maintenance.
## Primary Indications
* Treatment of peripheral neuropathy.
* Vitamin B12 deficiency (megaloblastic anemia).
* Adjunctive therapy for nerve damage or diabetic neuropathy.
## Adult Dosing
* **Peripheral Neuropathy:** 1500 mcg orally daily, divided into three doses (500 mcg TID).
* **Severe Deficiency:** Intramuscular (IM) or subcutaneous (SC) administration may be required; dosing varies significantly based on lab values and underlying pathology.
* *Note:* Oral absorption is highly dependent on intrinsic factor; if deficiency is due to malabsorption (e.g., pernicious anemia), parenteral administration is preferred.
## Pediatric Dosing
* **General Deficiency:** No standard pediatric protocol for methylcobalamin exists. Dosing is off-label and provider-specific.
* **Common Practice:** Typically 100–500 mcg orally daily, depending on nutritional status and underlying metabolic disorders. Consult a pediatric specialist or local institutional pharmacy protocol.
## Dose Adjustments
* **Renal Impairment:** No standard adjustment required, but use caution as cyanocobalamin accumulation is a theoretical concern in severe chronic kidney disease (CKD).
* **Hepatic Impairment:** No specific adjustment necessary.
## Contraindications
* Hypersensitivity to cobalt or any component of the formulation.
* Leber's optic atrophy (may precipitate rapid nerve damage).
## Adverse Effects
* **Common:** GI upset (diarrhea, nausea), mild skin rash, headache.
* **Serious:** Anaphylaxis (rare, usually associated with parenteral administration).
* **Hypokalemia:** Reported early in the treatment of severe megaloblastic anemia as rapid erythropoiesis consumes potassium.
## Key Drug Interactions
* **Chloramphenicol:** May antagonize the hematopoietic response to B12.
* **Colchicine/Heavy Alcohol Use/H2-Blockers/PPIs:** May reduce oral absorption of B12.
* **Metformin:** Long-term use is associated with decreased B12 absorption; monitor levels periodically.
## Monitoring
* **Laboratory:** Serum Vitamin B12 levels, complete blood count (CBC) to monitor resolution of anemia, and serum potassium levels (especially during initial treatment of severe anemia).
* **Clinical:** Resolution of neuropathic symptoms or paresthesias.
## Clinical Pearls
* **Bioavailability:** Oral bioavailability is extremely low (approx. 1%). High-dose oral therapy (500–1000 mcg) is often utilized to allow for passive diffusion when intrinsic factor levels are low or absent.
* **Formulation:** Patients may confuse methylcobalamin with cyanocobalamin. Methylcobalamin is often preferred in clinical practice for neurological indications, though evidence quality varies.
* **Storage:** Protect from light; methylcobalamin is light-sensitive and decomposes upon exposure.
***
**Educational Disclaimer:** This information is provided for educational purposes only. Clinical protocols, dosing guidelines, and availability vary by region and institution. Always verify dosages and safety information against current, local institutional prescribing guidelines and primary literature before administration.
